Single Dose, Double-blind, Placebo-controlled, Single Center, Randomized Cross-over Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetic Properties of BAY63-2521 After Oral Dosing in 20 Patients With Raynaud's Phenomenon (RP)
Phase of Trial: Phase II
Latest Information Update: 20 Sep 2018
Price : $35 *
At a glance
- Drugs Riociguat (Primary)
- Indications Raynaud's disease
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Acronyms DIGIT
- Sponsors Bayer
- 20 Sep 2018 Results published in the Clinical Drug Investigation
- 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
- 13 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.